1 | EU-approved RoActemra | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2 | RoActemra | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 11件: 40 40, 41, 44, 46, 50, 51, 86, 107, 266, 271, 331 💬 |
3 | RoActemra (R) | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
5 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
6 | RoActemra 162 mg | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
7 | RoActemra 162 mg solution for injection in pre-filled syringe | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
8 | RoActemra 162 mg solution injectable en seringue préremplie | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
9 | RoActemra 162 mg soluzione iniettabile in siringa preriempita | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 50 50 💬 |
10 | RoActemra 20 mg/ml concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
11 | RoActemra 20 mg/ml Concentrate for solution for infusion | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
12 | RoActemra 20 mg/ml concentrate for solution for infusion. | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
13 | ROACTEMRA 20 mg/ml, concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 46 46, 107, 271 💬 |
14 | RoActemra 20mg/ml | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 40 40 💬 |
15 | RoActemra(R) | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
16 | RoActemra/Actemra (tocilizumab) | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 107 107 💬 |
17 | RoActemra® | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 271 💬 |
18 | RoActemra® 20mg/ml Konzentrat | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 💬 |
19 | RoActemra®EV Product Code: PRD82321 | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
20 | Tocilizumab (Actemra or RoActemra) | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
21 | Tocilizumab [RoActemra/Actemra] | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 46 46, 51, 107, 331 💬 |
22 | Tocilizumab [RoActemra] | 1件: Tocilizumab Tocilizumab (Roactemra) | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |